Dr. Parsons Discusses the Role of PARP 7 in Overall Survival of Patients With Ovarian Cancer

Lavanya Palavalli Parsons, MD, clinical fellow, The University of Texas Southwestern Medical Center, discusses the role of PARP 7 in overall survival of patients with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.

PARP belongs to a large family, but the PARP inhibitors that are currently approved only target a select few PARPs, Parsons notes. Her research focused on exploring the other PARPs and if they had a relationship to ovarian cancer.

Parsons found that PARP 7 was amplified in many patients with ovarian cancer, which caused them to have an overall survival benefit.